Weekly Wrap

Research evidence excerpt

Weekly Wrap

ous non-small cell lung cancer,

and is one of the cornerstone studies underpinning the asset’s commercial case in lung. The

slip extends the timeline to any TIGIT-class validation in a setting where prior bispecific and

TIGIT readouts have disappointed, and defers a key catalyst for AstraZeneca’s post-Tagrisso

oncology pipeline.

Sobi receives Complete Response Letter: Sobi received a Complete Response Letter (CRL)

for chronic gout asset NASP/SEL-212, with the FDA requesting additional information on the

CMC and contract manufacturing package. This is broadly consistent with our view that the

filing carried greater risk than was widely appreciated, given the product's complexity and prior

management commentary on manufacturing. While the CRL is likely to delay launch by 12–

18 months, the absence of any concerns with the clinical data package should limit any major

reassessment of the asset's long-term potential. Recent FDA correspondence also points to

broader quality systems, documentation and data integrity concerns at a key manufacturing

site, suggesting the issues extend beyond a narrow technical CMC deficiency. Consensus

forecasts NASP contributing just 0.5% of revenue in 2026, rising to 2% in 2027 and 3% in

2028, implying limited near-term earnings sensitivity. However, the stock is well owned, and

the outcome may be seen as a modest hit to management credibility. Sobi maintains that its

2030 ambitions remain unchanged, while the delayed launch could allow some planned SG&A

spending to be deferred given the gout sales force has not yet been fully hired.

Ipsen adds to haemato-oncology arsenal: Ipsen to acquire Kartos Therapeutics for up to

$1.75bn (of which $450m upfront and $1.3bn in potential milestone payments). Deal centres